FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Heffernan Mark 		2. Issuer Name and Ticker or Trading Symbol

Nexvet Biopharma plc [ NVET ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)

C/O NEXVET BIOPHARMA PLC, UNIT 5, SRAGH TECHNOLOGY PARK, RAHAN RD 		3. Date of Earliest Transaction (MM/DD/YYYY)

7/1/2017
(Street)

TULLAMORE, L2 R35 FR98
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares   7/1/2017     M    25000   A $.125   74167   D  
 
Ordinary Shares   7/1/2017     M    35643   A $.125   109810   D  
 
Ordinary Shares                  243587   I   By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C>   (1)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Share Units   $.125   7/1/2017     M         25000    7/1/2017   (2) 7/1/2020   Ordinary Shares   25000   $0   50000   D  
 
Restricted Share Units   $.125   7/1/2017     M         35643    7/1/2017   (3) 7/1/2020   Ordinary Shares   35643   $0   106929   D  
 

Explanation of Responses:
(1)  The reporting person and his spouse share voting and dispositive power with respect to these reported securities.
(2)  25,000 of the Restricted Share Units vested and became convertible on 7/1/17 and 25,000 of the Restricted Share Units shall vest and become convertible on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.
(3)  35,643 of the Restricted Share Units vested and became convertible on 7/1/17 and 35,643 of the Restricted Share Units shall vest and become convertible on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Heffernan Mark
C/O NEXVET BIOPHARMA PLC
UNIT 5, SRAGH TECHNOLOGY PARK, RAHAN RD
TULLAMORE, L2 R35 FR98

Chief Executive Officer

Signatures
/s/ Mark Heffernan by Geraldine T. Farrell, Attorney-in-Fact 7/3/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 NEXVET BIOPHARMA PLC 차트를 더 보려면 여기를 클릭.
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 NEXVET BIOPHARMA PLC 차트를 더 보려면 여기를 클릭.